Estée Lauder Invests in 111SKIN, Signals Shift to Clinical Skin Care

Event summary

  • Estée Lauder Companies has taken a minority stake in luxury clinical skincare brand 111SKIN, founded by Dr. Yannis Alexandrides.
  • 111SKIN, established in 2012, initially developed products for post-surgical healing, centered around the NAC Y2™ complex.
  • The brand generates approximately 20% of revenue through direct-to-consumer channels, with North America accounting for 40% of 2025 sales.
  • Terms of the investment were not disclosed, and Dr. Alexandrides will remain actively involved in the brand.

The big picture

Estée Lauder’s investment in 111SKIN underscores the growing convergence of cosmetic procedures, preventative skincare, and consumer demand for visible results. The move aligns with the company’s ‘Beauty Reimagined’ vision and reflects a broader trend toward science-backed, clinical-grade skincare commanding premium pricing. While the deal size remains undisclosed, it signals Estée Lauder’s willingness to invest in smaller, high-growth brands to bolster its portfolio and capture emerging consumer segments.

What we're watching

Brand Integration
How Estée Lauder will integrate 111SKIN’s distribution channels and product portfolio without diluting the brand’s clinical credibility and direct-to-consumer appeal will be crucial for realizing the investment’s potential.
Consumer Adoption
Whether 111SKIN’s clinical-inspired approach can sustain its growth trajectory as broader consumer preferences shift and competition intensifies within the luxury skincare market remains to be seen.
NAC Y2™
The pace at which Estée Lauder can leverage and expand the application of 111SKIN’s NAC Y2™ technology across its existing product lines will indicate the strategic value of the acquisition.

Related topics

Revenue Growth